Key result
Erythropoietin use in dialysis patients is linked to hypertensive posterior leukoencephalopathy with neuroimaging changes in ~67%.
Case Report (n=6)
Answers are grounded in this paper and cite their sources.
Human recombinant erythropoietin is used to treat chronic anemia in patients with end-stage renal failure. Erythropoietin causes hypertension, and hypertensive encephalopathy has been associated with its use. We describe six dialysis-dependent, chronic renal failure patients who developed hypertension, headache, and seizures while on erythropoietin. Four of the six patients had posterior white matter changes on neuroimaging. The encephalopathy was managed by prompt antihypertensive and anticonvulsant treatment and by discontinuation of erythropoietin. Hypertensive posterior leukoencephalopathy is associated with erythropoietin use.
No takes yet. Share an insight, caveat, or question.
Delanty et al. (1997) conducted a case report in End-stage renal failure with chronic anemia (n=6). Erythropoietin was evaluated on Posterior white matter changes on neuroimaging. Erythropoietin use in dialysis-dependent chronic renal failure patients was associated with hypertensive posterior leukoencephalopathy, with neuroimaging changes in 4 of 6 cases.
Synapse has enriched 10 related papers. Consider them for comparative context: